

Claim Amendments

This listing of claims replaces all previous versions and listings of claims.

Listing of Claims

1-34. (Canceled)

35. (New) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of GLP-1 (SEQ ID NO. 3) to treat hypertension.

36. (New) The method of claim 35, wherein GLP-1 is administered peripherally.

37. (New) The method of claim 35, wherein GLP-1 is administered subcutaneously.

38. (New) The method of claim 35, wherein GLP-1 is administered intravenously.

39. (New) The method of claim 35, wherein the therapeutically effective amount is from 1 μ g to 5 mg per dose.

40. (New) The method of claim 35, wherein the administration is oral, buccal, pulmonary, nasal, intraocular, rectal, or transdermal.

41. (New) A method for treating hypertension in an individual in need thereof comprising peripherally administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising GLP-1 (SEQ ID NO. 3) and a pharmaceutically acceptable carrier to treat hypertension.

42. (New) The method of claim 40, whercin the pharmaceutical composition is a slow release composition.

43. (New) The method of claim 41, wherein the peripheral administration is subcutaneous.

44. (New) The method of claim 41, wherein the peripheral administration is intravenous.

45. (New) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a peptide having at least 95% sequence identity to GLP-1 (SEQ ID NO. 3) to treat hypertension.

46. (New) The method of claim 46, wherein GLP-1 is administered peripherally.

47. (New) The method of claim 46, wherein GLP-1 is administered subcutaneously.

48. (New) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a peptide having at least 90% sequence identity to GLP-1 (SEQ ID NO. 3) to treat hypertension.

49. (New) The method of claim 46, wherein GLP-1 is administered peripherally.

50. (New) The method of claim 46, wherein GLP-1 is administered subcutaneously.

51. (New) A method for treating hypertension in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a peptide having at least 70% sequence identity to GLP-1 (SEQ ID NO. 3) to treat hypertension.

52. (New) The method of claim 49, wherein GLP-1 is administered peripherally.

53. (New) The method of claim 49, wherein GLP-1 is administered subcutaneously.